Biocon Limited has informed the Exchange regarding a press release dated September 18, 2025, titled "Biocon Biologics Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases".
Press Release Sep 18 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Biocon
- Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases
- Press Release Sep 17 2025
- Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars
- Press Release Sep 12 2025
- Press Release Sep 11 2025
Later from Biocon
- Biocon Limited Press Release Oct 01 2025
- Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
- Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options
- Press Release Oct 16 2025
- Biocon Limited Press Release Oct 23 2025
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon